Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: IRAK-4 inhibitors - Aurigene Oncology/Curis

Next Previous
Drug Profile

Research programme: IRAK-4 inhibitors - Aurigene Oncology/Curis

Alternative Names: Interleukin-1 receptor-associated kinase 4 inhibitors - Aurigene Oncology/Curis; IRAK-4 inhibitors; IRAK4 kinase inhibitors - Aurigene Oncology/Curis

Latest Information Update: 21 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Oncology; Curis
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies; Inflammation

Most Recent Events

  • 31 Dec 2023 Curis files foreign patent applications for IRAK-4 inhibitory compounds before December 2023
  • 31 Dec 2023 Curis in-licenses IP rights from Aurigene for IRAK-4 inhibitory compounds in the US before December 2023
  • 28 May 2019 No recent reports of development identified for preclinical development in Inflammation in India (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top